GeneDx Holdings (WGS) Common Equity (2020 - 2026)

GeneDx Holdings has disclosed Common Equity across 7 years of filings, most recently posting $254.1 million for Q1 2026.

• In Q1 2026, Common Equity fell 1.27% year-over-year to $254.1 million; the TTM figure through Mar 2026 stood at $254.1 million (down 1.27% YoY), while the FY2025 annual figure was $308.2 million, up 25.66% from the prior year.
• Common Equity slipped to $254.1 million in Q1 2026, from $308.2 million in the prior quarter.
• Over the last five years, Common Equity for WGS reached as high as $637.3 million in Q2 2022 and fell as low as $194.0 million in Q2 2024.
• The 5-year median for Common Equity is $257.4 million (2025), against an average of $301.7 million.
• Annual changes were most pronounced in 2022 — Common Equity jumped 212.49% — and 2023, when it sank 54.7%.
• A 5-year view of Common Equity shows it stood at $253.7 million in 2022, then declined by 10.13% to $228.0 million in 2023, then gained by 7.56% to $245.2 million in 2024, then increased by 25.66% to $308.2 million in 2025, then retreated by 17.54% to $254.1 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $254.1 million, $308.2 million, and $292.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.